

Mã³nica Lopez-Guerra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5050353/publications.pdf>

Version: 2024-02-01

36
papers

4,042
citations

516561

16
h-index

477173

29
g-index

37
all docs

37
docs citations

37
times ranked

7085
citing authors

#	ARTICLE	IF	CITATIONS
1	Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , 2011, 475, 101-105.	13.7	1,364
2	Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2012, 44, 47-52.	9.4	893
3	Non-coding recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , 2015, 526, 519-524.	13.7	749
4	Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2012, 44, 1236-1242.	9.4	525
5	HHV8-related lymphoid proliferations: a broad spectrum of lesions from reactive lymphoid hyperplasia to overt lymphoma. <i>Modern Pathology</i> , 2017, 30, 745-760.	2.9	60
6	The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2015, 6, 22734-22749.	0.8	60
7	NF- κ B as a therapeutic target in chronic lymphocytic leukemia. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 275-288.	1.5	44
8	Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, 576-586.	1.7	40
9	p65 Activity and ZAP-70 Status Predict the Sensitivity of Chronic Lymphocytic Leukemia Cells to the Selective κ B Kinase Inhibitor BMS-345541. <i>Clinical Cancer Research</i> , 2009, 15, 2767-2776.	3.2	31
10	Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia. <i>Leukemia</i> , 2020, 34, 100-114.	3.3	31
11	Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 446.	3.5	28
12	Acute myeloid leukemia with <i>NPM1</i> mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. <i>British Journal of Haematology</i> , 2020, 191, 52-61.	1.2	28
13	European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. <i>Blood Advances</i> , 2022, 6, 1193-1206.	2.5	26
14	Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis. <i>Journal of Hepatology</i> , 2021, 74, 89-95.	1.8	25
15	Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells. <i>Oncogene</i> , 2020, 39, 1185-1197.	2.6	22
16	Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2008, 93, 1843-1851.	1.7	20
17	The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor- κ B mutational status. <i>Haematologica</i> , 2017, 102, e447-e451.	1.7	18
18	Clinicobiological features and outcome of patients with splenic marginal zone lymphoma with histological transformation. <i>British Journal of Haematology</i> , 2022, 196, 146-155.	1.2	17

#	ARTICLE	IF	CITATIONS
19	Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis. <i>Annals of Hematology</i> , 2019, 98, 2319-2328.	0.8	13
20	Essential thrombocythaemia with mutation in <i>MPL</i> : clinicopathological correlation and comparison with <i>JAK2V617F</i> -mutated and <i>CALR</i> -mutated genotypes. <i>Journal of Clinical Pathology</i> , 2018, 71, 975-980.	1.0	12
21	Clinicobiological Characteristics and Outcomes of Patients with T-Cell Large Granular Lymphocytic Leukemia and Chronic Lymphoproliferative Disorder of Natural Killer Cells from a Single Institution. <i>Cancers</i> , 2021, 13, 3900.	1.7	12
22	Conventional and molecular cytogenetic studies to characterize 2 complex variant Philadelphia translocations in patients with chronic myeloid leukemia. <i>Oncology Letters</i> , 2019, 17, 5705-5710.	0.8	5
23	Early T-cell precursor lymphoblastic leukaemia: response to FLAG-IDA and high-dose cytarabine with sorafenib after initial refractoriness. <i>British Journal of Haematology</i> , 2019, 185, 755-757.	1.2	5
24	New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1041-1052.	2.5	3
25	Prognostic Impact of <i>MYD88</i> L265P Mutation By Droplet Digital PCR in IgM MGUS and Smoldering Waldenström Macroglobulinemia. <i>Blood</i> , 2021, 138, 462-462.	0.6	3
26	Chronic lymphocytic leukaemia and prolymphocytic leukaemia. Two coins or two sides of the same coin?. <i>Haematologica</i> , 2020, 105, e484.	1.7	2
27	CXCR5-Mediated Shaping of the Lymphoid Follicle in Chronic Lymphocytic Leukemia. <i>Cancer Discovery</i> , 2014, 4, 1374-1376.	7.7	1
28	Challenges with Approved Targeted Therapies against Recurrent Mutations in CLL: A Place for New Actionable Targets. <i>Cancers</i> , 2021, 13, 3150.	1.7	1
29	<i>KMT2A-CBL</i> rearrangements in acute leukemias: clinical characteristics and genetic breakpoints. <i>Blood Advances</i> , 2021, 5, 5617-5620.	2.5	1
30	Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with <i>NPM1</i> Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol). <i>Blood</i> , 2018, 132, 1385-1385.	0.6	1
31	Clonal relationship in multisited mucosa-associated lymphoid tissue lymphomas: a single-centre experience. <i>British Journal of Haematology</i> , 2021, 192, 1020-1025.	1.2	1
32	Targeting IRAK4 Disrupts Inflammatory Pathways and Delays Tumor Development in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 2650-2650.	0.6	0
33	Triple Negative Myelofibrosis and Myelodysplastic Syndrome with Fibrosis: Clinico-Biological Characterization and Correlation with Gene Mutations. <i>Blood</i> , 2018, 132, 4299-4299.	0.6	0
34	Myeloproliferative/Myelodysplastic Neoplasms Presenting All Diagnostic Criteria of Chronic Myelomonocytic Leukemia but with Absolute Peripheral Blood Monocytosis 0.5-109/L Should be Classified As CMML. <i>Blood</i> , 2020, 136, 10-11.	0.6	0
35	Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012). <i>Blood</i> , 2020, 136, 31-32.	0.6	0
36	Abstract 2502: Unravelling the heterogenous molecular landscape of pediatric post-transplant lymphoproliferative disorders. <i>Cancer Research</i> , 2022, 82, 2502-2502.	0.4	0